Takeda Pharmaceutical Company Limited

Yoshihiro Banno

Koichiro Fukuda

Kazuaki Takami

Shigekazu Sasaki

Masahiro Kamaura

Satoru Oi

Ryosuke Tokunoh

Ryoma Hara

Yasushi Hattori

Tatsuki Koike

Tsuneo Yasuma

Tsuneo Oda

Hiroyuki Tawada

Nobuhiro Suzuki

Yasutaka Hoashi

Norihito Tokunaga

Takahiko Taniguchi

Yuichi Kajita

Nobuyuki Takakura

Yuhei Miyanohana

Keiko Kakegawa

Masaki Ogino

Minoru Sasaki

Takahiro Matsumoto

Atsuko Ochida

Yoshihide Tomata

Tohru Miyazaki

Kazuyoshi Aso

Shuji Kitamura

Zenichi Ikeda

Tatsuhiko Fujimoto

Fumiaki Kikuchi

Yoichi Nishikawa

Shogo Marui

Yoshito Terao

Kentaro Rikimaru

Yuji Ishichi

Hiromichi Sugimoto

Minoru Ikoma

Sachie Morimoto

Taihei Yamane

Koji Ikedou

Atsuko Nishiguchi

Kei Masuda

Koji Takeuchi

The present invention provides a production method suitable for industrial production of (2S,3S)-3-amino-2-(3-bromo-2-fluorobenzyl)pyrrolidine having a protecting group at the 1-position. The present invention is a method for producing N-[(4-methylphenyl)sulfonyl]-L-phenylalanine salt of (2S,3S)-3-amino-2-(3-bromo-2-fluorobenzyl)pyrrolidine having a protecting group at the 1-position, which comprises

Method for producing pyrrolidine compound

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

Heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]. 

Condensed heterocyclic compound

The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Aromatic ring compound

Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is &#x2014;O&#x2014; and the like; Ris a hydrogen atom and the like; Rand Rare each independently a hydrogen atom and the like; Ris an optionally substituted hydrocarbon group and the like; Ris a hydrogen atom and the like; and Ris &#x2014;(CH)&#x2014;COOH and the like, or a salt thereof.

Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; Rrepresents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; Rrepresents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents &#x2014;CO&#x2014;, &#x2014;CON(R)&#x2014;, COO&#x2014;, N(R)CON(R)&#x2014;, &#x2014;N(R)COO&#x2014;, &#x2014;N(R)SO&#x2014;, N(R)&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014; or &#x2014;SO&#x2014; (in which Rand Reach independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from;

Aromatic amine derivatives, their production and use

The present invention provides a compound of the formula: wherein ring A is an optionally substituted 5 to 10-membered aromatic ring; Rand Rare the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond and the like; and L is a divalent hydrocarbon group, and a salt thereof, except 3-(aminomethyl)-2,6,7-trimethyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-2-methyl-4-phenyl-1(2H)-isoquinolinone, 3-(aminomethyl)-6-chloro-2-methyl-4-phenyl-1(2H)-isoquinolinone and 3-(aminomethyl)-2-isopropyl-4-phenyl-1(2H)-isoquinolinone. The compound shows a superior peptidase-inhibitory activity and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

Fused heterocyclic compounds

Growing community of inventors

Kanagawa, Japan

Yoshihiro Banno